Abstract

Abstract Background: To investigate the relationship between pretreatment plasma EBV DNA copy number and sites and numbers of metastases in patients with nasopharyngeal carcinoma (NPC). Methods: One hundred and thirty-three patients with metastatic NPC were treated at outpatient department. Their plasma EBV DNA concentrations were determined by real-time quantitative PCR. Results: The overall patient response rate after 3-6 months of treatment was 48.1%. Pretreatment plasma EBV DNA concentrations were lower in patients with solitary nodule (≤5,000 copies/mL, 18/25 [72%] vs. multiple nodules, 49/128 [45.4%], P=0.025) or pure lung metastases (≤5,000 copies/mL, 19/21 [90.5%] vs. not lung metastases alone 48/112 [42.9%], P<0.001) and higher in patients with liver involvement, alone or combined with other organs (≤5,000 copies/mL, 18/54 [33.3%] vs. non-liver metastases 49/79 [62%], P=0.001); and bone related metastases (≤5,000 copies/mL, 33/83 [39.8%] vs. non-bone metastases 34/50 [68%], P=0.002). Moreover, plasma EBV DNA concentration was correlated with overall survival (OS) (≤5,000 vs. >5,000 copies/mL, median OS, 26 vs. 10 months; HR, 2.852; P<0.001). Conclusions: Pretreatment plasma EBV DNA copy number correlated with number and sites of metastases and with OS in patients with metastatic NPC. Citation Format: Hung-Ming Wang, Kai-Ping Chang, Tung-Liang Lin, Shiang-Fu Huang, Ngan-Ming Tsang, Sheng-Chieh Chan, Cheng-Lung Hsu. Correlation between number and sites of metastases and differential pretreated EBV DNA load profiles and their effects on outcomes in patients with metastatic nasopharyngeal carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2871. doi:10.1158/1538-7445.AM2014-2871

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call